American College of Cardiology's Annual Scientific Session & Expo 2022 (ACC.22)

Washington, DC, US 02 April 2022 - 04 April 2022

Post-TAVR SLT risk does not differ with edoxaban or DAPT

16 May 2022 by

The risk of subclinical valve leaflet thrombosis (SLT) following transcatheter aortic valve replacement (TAVR) did not differ regardless of whether patients received edoxaban or dual antiplatelet therapy (DAPT) post-surgery, according to results of the ADAPT-TAVR* trial.

16 May 2022

New HF guideline: Quad therapy, HFmrEF, and more

04 May 2022 by

Hot on the heels of ACC.22 ground-breaking reports, the ACC/AHA/HFSA* released the 2022 heart failure (HF) guideline, with special emphasis on quad therapy for patients with reduced ejection fraction.

04 May 2022

Exercise confers greater benefits in anxiety, depression

30 Apr 2022 by

The cardioprotective effects of exercise are nearly twice as large in people with anxiety and depression than in those without, suggests a new study presented at ACC.22.

30 Apr 2022

Adjunctive mavacamten averts need for invasive therapy in OHCM

28 Apr 2022 by

Adding mavacamten – an allosteric modulator of cardiac myosin – to maximal medical therapy slashes the need for septal reduction therapy (SRT) in patients with obstructive hypertrophic cardiomyopathy (OHCM) who are candidates for such intervention, the VALOR-HCM trial has shown.

28 Apr 2022

Annual flu jab in HF patients may lower hospitalization, pneumonia risk

27 Apr 2022 by

An annual influenza vaccination does not lower the risk of cardiovascular (CV) outcomes in patients with heart failure (HF), though it may reduce the risk of pneumonia and hospitalization, according to results of the IVVE study presented at ACC.22.

27 Apr 2022

Novel drug helps optimize HFrEF therapy

27 Apr 2022 by

In individuals receiving renin-angiotensin-aldosterone system inhibitor (RAASi) therapy for heart failure with reduced ejection fraction (HFrEF), the novel potassium binder patiromer effectively reduced serum potassium levels, the DIAMOND trial suggests, thus optimizing a guideline-directed RAASi therapy for these patients.

27 Apr 2022

Inflammation strong predictor of recurrent CV events in CKD

26 Apr 2022 by

Residual inflammation is a strong predictor of recurrent cardiovascular (CV) events than hyperlipidaemia in patients with atherosclerotic disease and impaired kidney function in a sub-study of the CANTOS* trial.

26 Apr 2022

Renal denervation aids in long-term blood pressure control

25 Apr 2022 by

Patients with uncontrolled hypertension can benefit from renal sympathetic denervation, which leads to notable reductions in systolic blood pressure (SBP) after 6 months of intervention, reports the proof-of-concept SPYRAL HTN-ON MED trial presented at ACC.22.

25 Apr 2022

CHAP backs BP control during pregnancy, even for mild hypertension

23 Apr 2022 by

Actively treating even mild hypertension to a target blood pressure (BP) of <140/90 mm Hg in pregnant women significantly lowers the risk of adverse pregnancy outcomes without apparent harm to the foetus compared with a strategy of reserving treatment to only when hypertension becomes severe (≥160/105 mm Hg), according to the CHAP* study presented at ACC 2022.

23 Apr 2022

Finerenone reduces CV events, renal outcomes in T2D-related CKD

22 Apr 2022 by

A pooled analysis of 13,171 patients from both the FIDELIO-DKD and FIGARO-DKD trials has confirmed the beneficial effects of finerenone, according to results of FIDELITY study, presented at the recently concluded American College of Cardiology Annual Scientific Session (ACC 2022).

22 Apr 2022